Atlantic Cod Trypsins: from Basic Research to Practical Applications Ágústa Gudmundsdóttir, Helga Margrét Pálsdóttir

Total Page:16

File Type:pdf, Size:1020Kb

Atlantic Cod Trypsins: from Basic Research to Practical Applications Ágústa Gudmundsdóttir, Helga Margrét Pálsdóttir Review ^OTCCmOLCX:Y Atlantic Cod Trypsins: From Basic Research to Practical Applications Ágústa Gudmundsdóttir, Helga Margrét Pálsdóttir Science Institute, University of Iceland, Læknagardi, Vatnsmÿrarvegi 16, Reykjavik, IS-101, Iceland Received: 27 May 2004 / Accepted: 24 June 2004/ Online publication: 15 March 2005 Abstract of exported goods from Iceland (Table 1). The decline of cod stocks in many areas has led to increased Atlantic cod trypsin I is an appropriate representa­ emphasis on cod farming. There is also heightened tive of the traditionally classified cold-adapted group awareness in many countries of the importance of I trypsins, and the recombinant form of cod trypsin Y increasing the value of seafood products by advanc­ is the only biochemically characterized member of ing the utilization of by-products from the fishing the novel group III trypsins. Trypsin Y is adapted to industries (Nafstad et aí., 2002; Rustad, 2003). The lower temperatures than all other presently known research presented here has been focused on that trypsins. This review describes the basic character­ issue from the beginning. istics of and practical uses for trypsins of Atlantic The pyloric cecum, serving the role of a digestive cod, as well as those of other organisms. Overex­ organ in the Atlantic cod, is a by-product of the pression of the recombinant forms of cod trypsins I fishing industry found in abundance in Iceland. As and Y in microorganisms is explained as well as the would be expected, it is rich in digestive enzymes advantages of using site-directed mutagenesis to in­ such as serine proteases (Asgeirsson et al., 1989). The crease their stability toward autolysis and thermal best known members of the serine protease family inactivation. Trypsins appear to play a key role in are trypsins, chymotrypsins, elastases, serine colla- the nutrition and development of marine fish. We genases, and brachyurins (Halfon and Craik, 1998). discuss the potential use of cod trypsins as biomar­ The serine proteases play important roles in a kers to evaluate the nutritional status of cod larvae number of biological functions. In digestion (Neu­ and describe the industrial applications of cod tryp­ rath, 1984) trypsin has a dual role in that it cleaves sin I and other trypsins. ingested proteins and activates the precursor forms of several other digestive proteases including chy- Key words: trypsins — fish — cold-adapted — motrypsin. Serine proteases from the Atlantic cod expression — practical applications such as trypsin (Asgeirsson et al., 1989), chymo- trypsin (Asgeirsson and Bjarnason, 1991), elastase (Asgeirsson and Bjarnason, 1993), and serine colla- Introduction genase (Kristjànsson et al., 1995) have typical char­ acteristics of cold-adapted enzymes. This review spans over two decades of research on The Atlantic cod is known to produce numer­ trypsins from the Atlantic cod (Gadus morhua). Its ous trypsin isozymes (Asgeirsson et al., 1989; main goal is to shed light on the basic properties of Gudmundsdóttir et al., 1993; Helgadóttir, 2002). these cold-adapted proteases as well as to view the Several of these have been isolated from their na­ numerous practical uses of trypsins from cod and tive source, with trypsin I being the most pre­ other organisms. The Atlantic cod is an economi­ dominant one. It also has the highest catalytic cally important fish species in Iceland and elsewhere efficiency and is by far the best characterized of in the Northern hemisphere. In 2002 cod products the trypsin isozymes (Asgeirsson et al., 1989; accounted for approximately 24% of the total value Jónsdóttir et al., 2004). The complementary DNAs of two trypsin isozymes (I and X) (Gudmundsdóttir et al., 1993), in addition to a novel trypsin termed Correspondence to: Ágústa Gudmundsdóttir,- E-mail: [email protected] trypsin Y (Spilliaert and Gudmundsdóttir, 1999), DOI: 10.1007/sl0126-004-0061-9 • Volume 7, 77-88 (2005) • © Springer Science+Business Media, Inc. 2005 77 78 Á g ú s t a G udmundsdóttir a n d H e lg a M a r g r é t P á l s d ó t t ir : A t l a n t ic C o d T r y psin s Table 1. Value of Exported Marine Products by Product Atlantic cod trypsin I has already proved useful Categories in 2002 Relative to All Exported Goods3 in industrial applications (Bjarnason et al., 1993; Product category Total (million ISK) (%) Value Bjarnason and Benediktsson, 2001) and medical All exported goods 204,000 100 applications (Bjarnason, 2000), as will be discussed Total marine products 129,000 63 later in this review. Other cold-adapted proteolytic Pelagic catch 25,000 12 enzymes have been applied as processing aids in the Demersal catch 78,000 38 food and feed industries, as was thoroughly described Cod products 49,000 24 in a review by Shahidi and Janak Kamil (2001). Other marine products 26,000 13 Sunde et al. (2001) demonstrated a significant “The value is given in million ISK (Icelandic kronas), fob. Also correlation between trypsin activity and the specific shown is the percentage value relative to all exported goods. Source: Statistics Iceland (External Trade, available at http:// growth rate of Atlantic salmon (Salmon salai). The www.hagstofan.is ). secretion rate of trypsin and chymotrypsin in marine fish has also been shown to be related to feed intake and filling of the stomach (Einarsson et al., 1996). have been isolated from a cod pyloric ceca cDNA Moreover, fish development appears to be highly library. Characterization of the recombinant tryp­ dependent on serine protease activity, and trypsin, in sin Y polypeptide demonstrated that it is very particular, has been suggested to play a key role in different from the classical trypsins, such as tryp­ larval survival (Porter and Theilacker, 1999). This is sin I (Pálsdóttir and Gudmundsdóttir, 2004), and due to the fact that trypsin activity, which is already may be the digestive enzyme produced under cold- present in fish larvae at first feeding or prior to the shock conditions (Roach 2002). development of the digestive system, is mainly In general trypsins from the Atlantic cod and responsible for the digestion of ingested food (Ko- other fish adapted to cold environments differ lovski, 2001). Trypsin is also a suitable short-term somewhat from their mammalian analogues in that indicator of nutritional quality in both farm-raised they have higher catalytic efficiencies, especially at and field-caught marine fish larvae (Nolting et al., low temperatures (Asgeirsson et al., 1989; Gerday 1999). Currently we are using knowledge about the et al., 2000; Schroder Leiros et al., 2000). These en­ Atlantic cod trypsins accumulated in our laboratory zymes are aiso more sensitive to inactivation by in the past in a research project aimed at increasing heat, low pH, and autolysis than their mesophilic the survival rate of farm-raised Atlantic cod larvae. analogues (Simpson et al., 1989; Asgeirsson et al., 1989). In addition, native proteins are easily hydro­ Trypsins I and Y lyzed by the cold-adapted fish proteases. These traits and the fact that the cold-adapted enzymes function Trypsin I. Most trypsins can be classified into 3 properly at low temperatures have stimulated inter­ basic groups, termed I, II, and III, based on their est in their commercial use, as they are generally amino acid sequence identities. The largest of these, better suited for enzymatic processes than their group I includes members like Atlantic cod trypsin I mesophilic counterparts (Bjarnason et al., 1993; and salmon trypsin I. All 3 trypsin groups, share the Bjarnason, 2000; Bjarnason and Benediktsson, 2001; catalytic triad residues His57, Aspl02, and Serl95 in Shahidi and Janak Kamil, 2001). addition to the obligatory Asp 189 localized at the The recent data presented on the expression of bottom of their substrate-binding pocket (Figure 1). Atlantic cod trypsin I (Jónsdóttir et al., 2004) and They also contain the Gly216 and Gly226 residues trypsin Y (Pálsdóttir and Gudmundsdóttir, 2004) are, lining the sides of the substrate-binding pocket and to our knowledge, the first reports on the expression Tyri 72, considered to be a key residue in trypsin of psychrophilic or cold-adapted proteolytic enzymes substrate specificity (Hedstrom et al., 1994). from fish in an active form. Difficulties related to the Three native trypsin isozymes, termed trypsins I, sensitivity of cold-adapted proteases to autolytic II, and III, were previously isolated from the pyloric degradation, thermal inactivation, as well as ceca of Atlantic cod and purified (Asgeirsson et al., molecular aggregation may account for the limited 1989). Trypsin I, the most abundant and best char­ number of publications in this area (Asgeirsson acterized form, also shows the highest catalytic et al., 1989; Asgeirsson and Bjarnason, 1991; Kris- efficiency (kcat/Km), which is approximately 20 times tjànsson et al., 1995; Helgadóttir, 2002). Site-directed higher than that of its mesophilic bovine analogue. mutagenesis of their cDNAs may be used to produce The high catalytic efficiency and low thermal sta­ new and improved recombinant enzyme variants bility of Atlantic cod trypsin I makes it an interest­ (Narinx et al., 1997; Benjamin et al., 2001; Gerike ing enzyme to study with respect to its structure- et al., 2001). function relationship. Atlantic cod trypsin I and Á g ú s t a G udmundsdóttir a n d H e l g a M a r g r é t P á l s d ó t t ir : A t l a n t ic C o d T r y p sin s 79 Group III -a 10 ia 30 40 30 57 60 70 w[ qJn p y A Q 1 A V V G D H H 1 WM Y E P olivaceus 3 M 1 G L i v [ l]
Recommended publications
  • A Chymotrypsin from the Digestive Tract of California Spiny Lobster, Panulirus Interruptus: Purification and Biochemical Characterization
    A chymotrypsin from the Digestive Tract of California Spiny Lobster, Panulirus interruptus: Purification and Biochemical Characterization Betsaida Bibo-Verdugo, Liliana Rojo- Arreola, Maria A. Navarrete-del-Toro & Fernando García-Carreño Marine Biotechnology An International Journal Focusing on Marine Genomics, Molecular Biology and Biotechnology ISSN 1436-2228 Volume 17 Number 4 Mar Biotechnol (2015) 17:416-427 DOI 10.1007/s10126-015-9626-z 1 23 Your article is protected by copyright and all rights are held exclusively by Springer Science +Business Media New York. This e-offprint is for personal use only and shall not be self- archived in electronic repositories. If you wish to self-archive your article, please use the accepted manuscript version for posting on your own website. You may further deposit the accepted manuscript version in any repository, provided it is only made publicly available 12 months after official publication or later and provided acknowledgement is given to the original source of publication and a link is inserted to the published article on Springer's website. The link must be accompanied by the following text: "The final publication is available at link.springer.com”. 1 23 Author's personal copy Mar Biotechnol (2015) 17:416–427 DOI 10.1007/s10126-015-9626-z ORIGINAL ARTICLE A chymotrypsin from the Digestive Tract of California Spiny Lobster, Panulirus interruptus: Purification and Biochemical Characterization Betsaida Bibo-Verdugo1 & Liliana Rojo-Arreola1 & Maria A. Navarrete-del-Toro1 & Fernando García-Carreño1 Received: 13 August 2014 /Accepted: 31 January 2015 /Published online: 16 April 2015 # Springer Science+Business Media New York 2015 Abstract A chymotrypsin was purified from the gastric juice Introduction of California spiny lobster (Panulirus interrutpus), using pre- parative electrophoresis and affinity chromatography on aga- Proteolytic enzymes from the digestive system of crustacean rose-p-aminobenzamidine.
    [Show full text]
  • Serine Proteases with Altered Sensitivity to Activity-Modulating
    (19) & (11) EP 2 045 321 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 08.04.2009 Bulletin 2009/15 C12N 9/00 (2006.01) C12N 15/00 (2006.01) C12Q 1/37 (2006.01) (21) Application number: 09150549.5 (22) Date of filing: 26.05.2006 (84) Designated Contracting States: • Haupts, Ulrich AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 51519 Odenthal (DE) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • Coco, Wayne SK TR 50737 Köln (DE) •Tebbe, Jan (30) Priority: 27.05.2005 EP 05104543 50733 Köln (DE) • Votsmeier, Christian (62) Document number(s) of the earlier application(s) in 50259 Pulheim (DE) accordance with Art. 76 EPC: • Scheidig, Andreas 06763303.2 / 1 883 696 50823 Köln (DE) (71) Applicant: Direvo Biotech AG (74) Representative: von Kreisler Selting Werner 50829 Köln (DE) Patentanwälte P.O. Box 10 22 41 (72) Inventors: 50462 Köln (DE) • Koltermann, André 82057 Icking (DE) Remarks: • Kettling, Ulrich This application was filed on 14-01-2009 as a 81477 München (DE) divisional application to the application mentioned under INID code 62. (54) Serine proteases with altered sensitivity to activity-modulating substances (57) The present invention provides variants of ser- screening of the library in the presence of one or several ine proteases of the S1 class with altered sensitivity to activity-modulating substances, selection of variants with one or more activity-modulating substances. A method altered sensitivity to one or several activity-modulating for the generation of such proteases is disclosed, com- substances and isolation of those polynucleotide se- prising the provision of a protease library encoding poly- quences that encode for the selected variants.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110747 A1 Ramseier Et Al
    US 200601 10747A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110747 A1 Ramseier et al. (43) Pub. Date: May 25, 2006 (54) PROCESS FOR IMPROVED PROTEIN (60) Provisional application No. 60/591489, filed on Jul. EXPRESSION BY STRAIN ENGINEERING 26, 2004. (75) Inventors: Thomas M. Ramseier, Poway, CA Publication Classification (US); Hongfan Jin, San Diego, CA (51) Int. Cl. (US); Charles H. Squires, Poway, CA CI2O I/68 (2006.01) (US) GOIN 33/53 (2006.01) CI2N 15/74 (2006.01) Correspondence Address: (52) U.S. Cl. ................................ 435/6: 435/7.1; 435/471 KING & SPALDING LLP 118O PEACHTREE STREET (57) ABSTRACT ATLANTA, GA 30309 (US) This invention is a process for improving the production levels of recombinant proteins or peptides or improving the (73) Assignee: Dow Global Technologies Inc., Midland, level of active recombinant proteins or peptides expressed in MI (US) host cells. The invention is a process of comparing two genetic profiles of a cell that expresses a recombinant (21) Appl. No.: 11/189,375 protein and modifying the cell to change the expression of a gene product that is upregulated in response to the recom (22) Filed: Jul. 26, 2005 binant protein expression. The process can improve protein production or can improve protein quality, for example, by Related U.S. Application Data increasing solubility of a recombinant protein. Patent Application Publication May 25, 2006 Sheet 1 of 15 US 2006/0110747 A1 Figure 1 09 010909070£020\,0 10°0 Patent Application Publication May 25, 2006 Sheet 2 of 15 US 2006/0110747 A1 Figure 2 Ester sers Custer || || || || || HH-I-H 1 H4 s a cisiers TT closers | | | | | | Ya S T RXFO 1961.
    [Show full text]
  • Larval Peritrophic Matrix Yu-Bo Lin1,2†, Jing-Jing Rong1,2†, Xun-Fan Wei3, Zhuo-Xiao Sui3, Jinhua Xiao3 and Da-Wei Huang3*
    Lin et al. Proteome Science (2021) 19:7 https://doi.org/10.1186/s12953-021-00175-x RESEARCH Open Access Proteomics and ultrastructural analysis of Hermetia illucens (Diptera: Stratiomyidae) larval peritrophic matrix Yu-Bo Lin1,2†, Jing-Jing Rong1,2†, Xun-Fan Wei3, Zhuo-Xiao Sui3, Jinhua Xiao3 and Da-Wei Huang3* Abstract Background: The black soldier fly (Hermetia illucens) has significant economic potential. The larvae can be used in financially viable waste management systems, as they are voracious feeders able to efficiently convert low-quality waste into valuable biomass. However, most studies on H. illucens in recent decades have focused on optimizing their breeding and bioconversion conditions, while information on their biology is limited. Methods: About 200 fifth instar well-fed larvae were sacrificed in this work. The liquid chromatography-tandem mass spectrometry and scanning electron microscopy were employed in this study to perform a proteomic and ultrastructural analysis of the peritrophic matrix (PM) of H. illucens larvae. Results: A total of 565 proteins were identified in the PM samples of H. illucen, of which 177 proteins were predicted to contain signal peptides, bioinformatics analysis and manual curation determined 88 proteins may be associated with the PM, with functions in digestion, immunity, PM modulation, and others. The ultrastructure of the H. illucens larval PM observed by scanning electron microscopy shows a unique diamond-shaped chitin grid texture. Conclusions: It is the first and most comprehensive proteomics research about the PM of H. illucens larvae to date. All the proteins identified in this work has been discussed in details, except several unnamed or uncharacterized proteins, which should not be ignored and need further study.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2004/0081648A1 Afeyan Et Al
    US 2004.008 1648A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0081648A1 Afeyan et al. (43) Pub. Date: Apr. 29, 2004 (54) ADZYMES AND USES THEREOF Publication Classification (76) Inventors: Noubar B. Afeyan, Lexington, MA (51) Int. Cl." ............................. A61K 38/48; C12N 9/64 (US); Frank D. Lee, Chestnut Hill, MA (52) U.S. Cl. ......................................... 424/94.63; 435/226 (US); Gordon G. Wong, Brookline, MA (US); Ruchira Das Gupta, Auburndale, MA (US); Brian Baynes, (57) ABSTRACT Somerville, MA (US) Disclosed is a family of novel protein constructs, useful as Correspondence Address: drugs and for other purposes, termed “adzymes, comprising ROPES & GRAY LLP an address moiety and a catalytic domain. In Some types of disclosed adzymes, the address binds with a binding site on ONE INTERNATIONAL PLACE or in functional proximity to a targeted biomolecule, e.g., an BOSTON, MA 02110-2624 (US) extracellular targeted biomolecule, and is disposed adjacent (21) Appl. No.: 10/650,592 the catalytic domain So that its affinity Serves to confer a new Specificity to the catalytic domain by increasing the effective (22) Filed: Aug. 27, 2003 local concentration of the target in the vicinity of the catalytic domain. The present invention also provides phar Related U.S. Application Data maceutical compositions comprising these adzymes, meth ods of making adzymes, DNA's encoding adzymes or parts (60) Provisional application No. 60/406,517, filed on Aug. thereof, and methods of using adzymes, Such as for treating 27, 2002. Provisional application No. 60/423,754, human Subjects Suffering from a disease, Such as a disease filed on Nov.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,561,811 B2 Bluchel Et Al
    USOO8561811 B2 (12) United States Patent (10) Patent No.: US 8,561,811 B2 Bluchel et al. (45) Date of Patent: Oct. 22, 2013 (54) SUBSTRATE FOR IMMOBILIZING (56) References Cited FUNCTIONAL SUBSTANCES AND METHOD FOR PREPARING THE SAME U.S. PATENT DOCUMENTS 3,952,053 A 4, 1976 Brown, Jr. et al. (71) Applicants: Christian Gert Bluchel, Singapore 4.415,663 A 1 1/1983 Symon et al. (SG); Yanmei Wang, Singapore (SG) 4,576,928 A 3, 1986 Tani et al. 4.915,839 A 4, 1990 Marinaccio et al. (72) Inventors: Christian Gert Bluchel, Singapore 6,946,527 B2 9, 2005 Lemke et al. (SG); Yanmei Wang, Singapore (SG) FOREIGN PATENT DOCUMENTS (73) Assignee: Temasek Polytechnic, Singapore (SG) CN 101596422 A 12/2009 JP 2253813 A 10, 1990 (*) Notice: Subject to any disclaimer, the term of this JP 2258006 A 10, 1990 patent is extended or adjusted under 35 WO O2O2585 A2 1, 2002 U.S.C. 154(b) by 0 days. OTHER PUBLICATIONS (21) Appl. No.: 13/837,254 Inaternational Search Report for PCT/SG2011/000069 mailing date (22) Filed: Mar 15, 2013 of Apr. 12, 2011. Suen, Shing-Yi, et al. “Comparison of Ligand Density and Protein (65) Prior Publication Data Adsorption on Dye Affinity Membranes Using Difference Spacer Arms'. Separation Science and Technology, 35:1 (2000), pp. 69-87. US 2013/0210111A1 Aug. 15, 2013 Related U.S. Application Data Primary Examiner — Chester Barry (62) Division of application No. 13/580,055, filed as (74) Attorney, Agent, or Firm — Cantor Colburn LLP application No.
    [Show full text]
  • All Enzymes in BRENDA™ the Comprehensive Enzyme Information System
    All enzymes in BRENDA™ The Comprehensive Enzyme Information System http://www.brenda-enzymes.org/index.php4?page=information/all_enzymes.php4 1.1.1.1 alcohol dehydrogenase 1.1.1.B1 D-arabitol-phosphate dehydrogenase 1.1.1.2 alcohol dehydrogenase (NADP+) 1.1.1.B3 (S)-specific secondary alcohol dehydrogenase 1.1.1.3 homoserine dehydrogenase 1.1.1.B4 (R)-specific secondary alcohol dehydrogenase 1.1.1.4 (R,R)-butanediol dehydrogenase 1.1.1.5 acetoin dehydrogenase 1.1.1.B5 NADP-retinol dehydrogenase 1.1.1.6 glycerol dehydrogenase 1.1.1.7 propanediol-phosphate dehydrogenase 1.1.1.8 glycerol-3-phosphate dehydrogenase (NAD+) 1.1.1.9 D-xylulose reductase 1.1.1.10 L-xylulose reductase 1.1.1.11 D-arabinitol 4-dehydrogenase 1.1.1.12 L-arabinitol 4-dehydrogenase 1.1.1.13 L-arabinitol 2-dehydrogenase 1.1.1.14 L-iditol 2-dehydrogenase 1.1.1.15 D-iditol 2-dehydrogenase 1.1.1.16 galactitol 2-dehydrogenase 1.1.1.17 mannitol-1-phosphate 5-dehydrogenase 1.1.1.18 inositol 2-dehydrogenase 1.1.1.19 glucuronate reductase 1.1.1.20 glucuronolactone reductase 1.1.1.21 aldehyde reductase 1.1.1.22 UDP-glucose 6-dehydrogenase 1.1.1.23 histidinol dehydrogenase 1.1.1.24 quinate dehydrogenase 1.1.1.25 shikimate dehydrogenase 1.1.1.26 glyoxylate reductase 1.1.1.27 L-lactate dehydrogenase 1.1.1.28 D-lactate dehydrogenase 1.1.1.29 glycerate dehydrogenase 1.1.1.30 3-hydroxybutyrate dehydrogenase 1.1.1.31 3-hydroxyisobutyrate dehydrogenase 1.1.1.32 mevaldate reductase 1.1.1.33 mevaldate reductase (NADPH) 1.1.1.34 hydroxymethylglutaryl-CoA reductase (NADPH) 1.1.1.35 3-hydroxyacyl-CoA
    [Show full text]
  • Next-Generation Sequencing Analysis of the Tineola Bisselliella Larval Gut Transcriptome Reveals Candidate Enzymes for Keratin Digestion
    G C A T T A C G G C A T genes Article Next-Generation Sequencing Analysis of the Tineola bisselliella Larval Gut Transcriptome Reveals Candidate Enzymes for Keratin Digestion Michael Schwabe 1, Sven Griep 2 , Henrike Schmidtberg 3, Rudy Plarre 4, Alexander Goesmann 2, Andreas Vilcinskas 1,3 , Heiko Vogel 5 and Karina Brinkrolf 2,* 1 Department of Bioresources, Fraunhofer Institute for Molecular Biology and Applied Ecology, Ohlebergsweg 12, 35392 Giessen, Germany; [email protected] (M.S.); [email protected] (A.V.) 2 Bioinformatics and Systems Biology, Justus Liebig University Giessen, Heinrich-Buff-Ring 58, 35392 Giessen, Germany; [email protected] (S.G.); [email protected] (A.G.) 3 Institute for Insect Biotechnology, Justus Liebig University Giessen, Heinrich-Buff-Ring 26-32, 35392 Giessen, Germany; [email protected] 4 Bundesanstalt für Materialforschung und -prüfung (BAM), Unter den Eichen 87, 12205 Berlin, Germany; [email protected] 5 Entomology Department, Max-Planck Institute for Chemical Ecology, Hans-Knoell-Strasse 8, 07745 Jena, Germany; [email protected] * Correspondence: [email protected]; Tel.: +49-641-99-35807 Citation: Schwabe, M.; Griep, S.; Abstract: The clothes moth Tineola bisselliella is one of a few insects that can digest keratin, leading Schmidtberg, H.; Plarre, R.; to the destruction of clothing, textiles and artwork. The mechanism of keratin digestion is not yet Goesmann, A.; Vilcinskas, A.; Vogel, fully understood, partly reflecting the lack of publicly available genomic and transcriptomic data. H.; Brinkrolf, K. Next-Generation Here we present a high-quality gut transcriptome of T.
    [Show full text]
  • Supplementary Material (ESI) for Natural Product Reports
    Electronic Supplementary Material (ESI) for Natural Product Reports. This journal is © The Royal Society of Chemistry 2014 Supplement to the paper of Alexey A. Lagunin, Rajesh K. Goel, Dinesh Y. Gawande, Priynka Pahwa, Tatyana A. Gloriozova, Alexander V. Dmitriev, Sergey M. Ivanov, Anastassia V. Rudik, Varvara I. Konova, Pavel V. Pogodin, Dmitry S. Druzhilovsky and Vladimir V. Poroikov “Chemo- and bioinformatics resources for in silico drug discovery from medicinal plants beyond their traditional use: a critical review” Contents PASS (Prediction of Activity Spectra for Substances) Approach S-1 Table S1. The lists of 122 known therapeutic effects for 50 analyzed medicinal plants with accuracy of PASS prediction calculated by a leave-one-out cross-validation procedure during the training and number of active compounds in PASS training set S-6 Table S2. The lists of 3,345 mechanisms of action that were predicted by PASS and were used in this study with accuracy of PASS prediction calculated by a leave-one-out cross-validation procedure during the training and number of active compounds in PASS training set S-9 Table S3. Comparison of direct PASS prediction results of known effects for phytoconstituents of 50 TIM plants with prediction of known effects through “mechanism-effect” and “target-pathway- effect” relationships from PharmaExpert S-79 S-1 PASS (Prediction of Activity Spectra for Substances) Approach PASS provides simultaneous predictions of many types of biological activity (activity spectrum) based on the structure of drug-like compounds. The approach used in PASS is based on the suggestion that biological activity of any drug-like compound is a function of its structure.
    [Show full text]
  • Springer Handbook of Enzymes
    Dietmar Schomburg Ida Schomburg (Eds.) Springer Handbook of Enzymes Alphabetical Name Index 1 23 © Springer-Verlag Berlin Heidelberg New York 2010 This work is subject to copyright. All rights reserved, whether in whole or part of the material con- cerned, specifically the right of translation, printing and reprinting, reproduction and storage in data- bases. The publisher cannot assume any legal responsibility for given data. Commercial distribution is only permitted with the publishers written consent. Springer Handbook of Enzymes, Vols. 1–39 + Supplements 1–7, Name Index 2.4.1.60 abequosyltransferase, Vol. 31, p. 468 2.7.1.157 N-acetylgalactosamine kinase, Vol. S2, p. 268 4.2.3.18 abietadiene synthase, Vol. S7,p.276 3.1.6.12 N-acetylgalactosamine-4-sulfatase, Vol. 11, p. 300 1.14.13.93 (+)-abscisic acid 8’-hydroxylase, Vol. S1, p. 602 3.1.6.4 N-acetylgalactosamine-6-sulfatase, Vol. 11, p. 267 1.2.3.14 abscisic-aldehyde oxidase, Vol. S1, p. 176 3.2.1.49 a-N-acetylgalactosaminidase, Vol. 13,p.10 1.2.1.10 acetaldehyde dehydrogenase (acetylating), Vol. 20, 3.2.1.53 b-N-acetylgalactosaminidase, Vol. 13,p.91 p. 115 2.4.99.3 a-N-acetylgalactosaminide a-2,6-sialyltransferase, 3.5.1.63 4-acetamidobutyrate deacetylase, Vol. 14,p.528 Vol. 33,p.335 3.5.1.51 4-acetamidobutyryl-CoA deacetylase, Vol. 14, 2.4.1.147 acetylgalactosaminyl-O-glycosyl-glycoprotein b- p. 482 1,3-N-acetylglucosaminyltransferase, Vol. 32, 3.5.1.29 2-(acetamidomethylene)succinate hydrolase, p. 287 Vol.
    [Show full text]
  • Proteomics Based Process and Cell Line Development Applied to A
    Proteomics Based Process and Cell Line Development Applied to a Mammalian Therapeutic Enzyme A thesis submitted to University College London for the degree of Doctor of Biochemical Engineering by Damiano Migani 2017 Department of Biochemical Engineering, University College London Bernard Katz Building, Gower Street London WC1E 6BT Declaration I, Damiano Migani, confirm that the work presented in this thesis is my own. Where information had been derived from other sources, I confirm that this has been indicated in the thesis. 2 Table of Contents Table of Contents ....................................................................................................................... 3 Table of Figures ......................................................................................................................... 9 Table of Tables ........................................................................................................................ 11 1 Abstract ............................................................................................................................. 14 2 Introduction ...................................................................................................................... 15 2.1 Impact statement ....................................................................................................... 15 2.2 Literature review ....................................................................................................... 16 2.2.1 Biopharmaceutical industry ..............................................................................
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 7.282,360 B2 Meyers Et Al
    USOO7282,360B2 (12) United States Patent (10) Patent No.: US 7.282,360 B2 Meyers et al. (45) Date of Patent: Oct. 16, 2007 (54) HUMAN PROTEIN KINASE, PHOSPHATASE, provisional application No. 60/197.508, filed on Apr. AND PROTEASE FAMILY MEMBERS AND 18, 2000, provisional application No. 60/187,454, USES THEREOF filed on Mar. 7, 2000, provisional application No. 60/187.420, filed on Mar. 7, 2000, provisional appli (75) Inventors: Rachel E. Meyers, Newton, MA (US); cation No. 60/186,061, filed on Feb. 29, 2000. Peter J. Olandt, Newton, MA (US); Rosana Kapeller-Libermann, Chestnut (51) Int. Cl. Hill, MA (US); Rory A. J. Curtis, CI2N 9/20 (2006.01) Framingham, MA (US); Mark CI2N IS/00 (2006.01) Williamson, Saugus, MA (US); Nadine CI2N L/20 (2006.01) Weich, Brookline, MA (US) CI2O I/68 (2006.01) C7H 2L/04 (2006.01) (73) Assignee: Millennium Pharmaceuticals, Inc., (52) U.S. Cl. ................ 435/194; 435/320.1; 435/252.3: Cambridge, MA (US) 435/6:536/23.2 (58) Field of Classification Search ................ 435/194, *) Notice: Subject to anyy disclaimer, the term of this 435/6, 252.3, 320.1; 536/23.2 patent is extended or adjusted under 35 See application file for complete search history. U.S.C. 154(b) by 0 days. (56) References Cited (21) Appl. No.: 11/636,948 U.S. PATENT DOCUMENTS (22) Filed: Dec. 11, 2006 6,476,210 B2 * 1 1/2002 Turner et al. .............. 536,232 2004.0034.888 A1 2/2004 Liu et al. (65) Prior Publication Data US 2007/OO99274 A1 May 3, 2007 FOREIGN PATENT DOCUMENTS WO WOOOf73469 A2 12/2000 Related U.S.
    [Show full text]